{
    "abstract": "A new dengue vaccine was associated with increased risk of hospitalized virologically-confirmed disease during year 3 of follow-up among children age 2\u20135\u00a0years. Among hypotheses to explain this finding, we could not distinguish definitively between antibody dependent enhancement, waning immunity, or chance occurrence. However, any theory must account for the following: (a) the signal occurred mainly because of decreased dengue among controls rather than increased dengue among vaccinees; (b) among 48 data points, a statistically significant increase in hospitalization among vaccinated children occurred for only one age group, during one year, and in one region; (c) cumulative risk was similar for vaccinated vs. control children age 2\u20135\u00a0years at the end of year 5 and lower for vaccinated vs. control children among older age groups; (d) the protective effect of vaccine against hospitalization decreased from years 1\u20132 to years 3\u20135 of follow-up for all age groups and regions.",
    "author_highlights": [
        {
            "endOffset": 10665,
            "sentence": "Dengue vaccine was associated with increased risk of hospitalization during year 3 for young children in Asia.",
            "startOffset": 10555
        },
        {
            "endOffset": 10776,
            "sentence": "Currently published data cannot distinguish between immune enhancement, waning immunity, or chance occurrence.",
            "startOffset": 10666
        },
        {
            "endOffset": 10862,
            "sentence": "Taken as a whole, data are most consistent with waning immunity or chance occurrence.",
            "startOffset": 10777
        },
        {
            "endOffset": 10946,
            "sentence": "This analysis supports appropriateness of countries using vaccine in endemic areas.",
            "startOffset": 10863
        },
        {
            "endOffset": 11053,
            "sentence": "Currently published data do not support a need to determine baseline serostatus before immunizing persons.",
            "startOffset": 10947
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Arunee",
                    "initial": "A.",
                    "last": "Sabchareon"
                },
                {
                    "first": "Derek",
                    "initial": "D.",
                    "last": "Wallace"
                },
                {
                    "first": "Chukiat",
                    "initial": "C.",
                    "last": "Sirivichayakul"
                },
                {
                    "first": "Kriengsak",
                    "initial": "K.",
                    "last": "Limkittikul"
                },
                {
                    "first": "Pornthep",
                    "initial": "P.",
                    "last": "Chanthavanich"
                },
                {
                    "first": "Saravudh",
                    "initial": "S.",
                    "last": "Suvannadabba"
                },
                {
                    "first": "Vithaya",
                    "initial": "V.",
                    "last": "Jiwariyavej"
                },
                {
                    "first": "Wut",
                    "initial": "W.",
                    "last": "Dulyachai"
                },
                {
                    "first": "Krisana",
                    "initial": "K.",
                    "last": "Pengsaa"
                },
                {
                    "first": "T. Anh",
                    "initial": "T.A.",
                    "last": "Wartel"
                },
                {
                    "first": "Annick",
                    "initial": "A.",
                    "last": "Moureau"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Bouckenooghe"
                },
                {
                    "first": "Simonetta",
                    "initial": "S.",
                    "last": "Viviani"
                },
                {
                    "first": "Nadia G.",
                    "initial": "N.G.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Lang"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61428-7",
            "firstpage": "1559",
            "issn": "01406736",
            "lastpage": "1567",
            "pmid": "22975340",
            "pub_year": 2012,
            "title": "Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial",
            "volume": "380"
        },
        "b0010": {
            "authors": [
                {
                    "first": "S. R.",
                    "initial": "S.R.",
                    "last": "Hadinegoro"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Arredondo-Garc\u00eda"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Capeding"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Deseda"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Chotpitayasunondh"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Dietze"
                },
                {
                    "first": "H. I.",
                    "initial": "H.I.",
                    "last": "Hj Muhammad Ismail"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Reynales"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Limkittikul"
                },
                {
                    "first": "D. M.",
                    "initial": "D.M.",
                    "last": "Rivera-Medina"
                },
                {
                    "first": "H. N.",
                    "initial": "H.N.",
                    "last": "Tran"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Bouckenooghe"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Chansinghakul"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Cort\u00e9s"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Fanouillere"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Forrat"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Frago"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Gailhardou"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Jackson"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Noriega"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Plennevaux"
                },
                {
                    "first": "T. A.",
                    "initial": "T.A.",
                    "last": "Wartel"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Zambrano"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1506223",
            "firstpage": "1195",
            "issn": "00284793",
            "lastpage": "1206",
            "pmid": "26214039",
            "pub_year": 2015,
            "title": "Efficacy and long-term safety of a dengue vaccine in regions of endemic disease",
            "volume": "373"
        },
        "b0015": null,
        "b0020": {
            "authors": [
                {
                    "first": "Scott B.",
                    "initial": "S.B.",
                    "last": "Halstead"
                },
                {
                    "first": "Philip K.",
                    "initial": "P.K.",
                    "last": "Russell"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.02.004",
            "firstpage": "1643",
            "issn": "0264410X",
            "lastpage": "1647",
            "pmid": "26873054",
            "pub_year": 2016,
            "title": "Protective and immunological behavior of chimeric yellow fever dengue vaccine",
            "volume": "34"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Sri Rezki S.",
                    "initial": "S.R.S.",
                    "last": "Hadinegoro"
                },
                {
                    "first": "Jose Luis",
                    "initial": "J.L.",
                    "last": "Arredondo-Garc\u00eda"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Guy"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Bouckenooghe"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "Noriega"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Jackson"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.06.015",
            "firstpage": "4273",
            "issn": "0264410X",
            "lastpage": "4274",
            "pmid": "27452651",
            "pub_year": 2016,
            "title": "Answer to the review from Halstead and Russell \u201cProtective and immunological behavior of chimeric yellow fever dengue vaccine\u201d (DOI 10.1016/j.vaccine.2016.02.004)",
            "volume": "34"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Timothy P.",
                    "initial": "T.P.",
                    "last": "Endy"
                }
            ],
            "doi": "10.3389/fimmu.2014.00183",
            "issn": "16643224",
            "pub_year": 2014,
            "title": "Human immune responses to dengue virus infection: Lessons learned from prospective cohort studies",
            "volume": "5"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Kathryn B.",
                    "initial": "K.B.",
                    "last": "Anderson"
                },
                {
                    "first": "Robert V.",
                    "initial": "R.V.",
                    "last": "Gibbons"
                },
                {
                    "first": "Derek A.T.",
                    "initial": "D.A.T.",
                    "last": "Cummings"
                },
                {
                    "first": "Ananda",
                    "initial": "A.",
                    "last": "Nisalak"
                },
                {
                    "first": "Sharone",
                    "initial": "S.",
                    "last": "Green"
                },
                {
                    "first": "Daniel H.",
                    "initial": "D.H.",
                    "last": "Libraty"
                },
                {
                    "first": "Richard G.",
                    "initial": "R.G.",
                    "last": "Jarman"
                },
                {
                    "first": "Anon",
                    "initial": "A.",
                    "last": "Srikiatkhachorn"
                },
                {
                    "first": "Mammen P.",
                    "initial": "M.P.",
                    "last": "Mammen"
                },
                {
                    "first": "Buddhari",
                    "initial": "B.",
                    "last": "Darunee"
                },
                {
                    "first": "In Kyu",
                    "initial": "I.K.",
                    "last": "Yoon"
                },
                {
                    "first": "Timothy P.",
                    "initial": "T.P.",
                    "last": "Endy"
                }
            ],
            "doi": "10.1093/infdis/jit436",
            "firstpage": "360",
            "issn": "00221899",
            "lastpage": "368",
            "pmid": "23964110",
            "pub_year": 2014,
            "title": "A shorter time interval between first and second dengue infections is associated with protection from clinical Illness in a school-based cohort in Thailand",
            "volume": "209"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Neil M.",
                    "initial": "N.M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Rodr\u00edguez-Barraquer"
                },
                {
                    "first": "Ilaria",
                    "initial": "I.",
                    "last": "Dorigatti"
                },
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "Mier-Y-Teran-Romero"
                },
                {
                    "first": "Daniel J.",
                    "initial": "D.J.",
                    "last": "Laydon"
                },
                {
                    "first": "Derek A.T.",
                    "initial": "D.A.T.",
                    "last": "Cummings"
                }
            ],
            "doi": "10.1126/science.aaf9590",
            "firstpage": "1033",
            "issn": "00368075",
            "lastpage": "1036",
            "pmid": "27701113",
            "pub_year": 2016,
            "title": "Benefits and risks of the sanofi-pasteur dengue vaccine: Modeling optimal deployment",
            "volume": "353"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Sophia",
                    "initial": "S.",
                    "last": "Gailhardou"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Skipetrova"
                },
                {
                    "first": "Gustavo H.",
                    "initial": "G.H.",
                    "last": "Dayan"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Jezorwski"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Van der Vliet"
                },
                {
                    "first": "T. Anh",
                    "initial": "T.A.",
                    "last": "Wartel"
                }
            ],
            "doi": "10.1371/journal.pntd.0004821",
            "issn": "19352727",
            "pmid": "27414655",
            "pub_year": 2016,
            "title": "Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials",
            "volume": "10"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Annelies",
                    "initial": "A.",
                    "last": "Wilder-Smith"
                },
                {
                    "first": "Kirsten S.",
                    "initial": "K.S.",
                    "last": "Vannice"
                },
                {
                    "first": "Joachim",
                    "initial": "J.",
                    "last": "Hombach"
                },
                {
                    "first": "Jeremy",
                    "initial": "J.",
                    "last": "Farrar"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                }
            ],
            "doi": "10.1093/infdis/jiw341",
            "firstpage": "1796",
            "issn": "00221899",
            "lastpage": "1799",
            "pmid": "27496977",
            "pub_year": 2016,
            "title": "Population perspectives and world health organization recommendations for cyd-tdv dengue vaccine",
            "volume": "214"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Bradford D.",
                    "initial": "B.D.",
                    "last": "Gessner"
                },
                {
                    "first": "Annelies",
                    "initial": "A.",
                    "last": "Wilder-Smith"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.03.017",
            "firstpage": "2397",
            "issn": "0264410X",
            "lastpage": "2401",
            "pmid": "27055020",
            "pub_year": 2016,
            "title": "Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate",
            "volume": "34"
        },
        "b0060": {
            "authors": [],
            "firstpage": "349",
            "issn": "00498114",
            "lastpage": "364",
            "pmid": "27476189",
            "pub_year": 2016,
            "title": "Dengue vaccine: WHO position paper \u2013 July 2016",
            "volume": "91"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": "Ilaria",
                    "initial": "I.",
                    "last": "Dorigatti"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "Aguas"
                },
                {
                    "first": "Christl A.",
                    "initial": "C.A.",
                    "last": "Donnelly"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Guy"
                },
                {
                    "first": "Laurent",
                    "initial": "L.",
                    "last": "Coudeville"
                },
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Jackson"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": "Neil M.",
                    "initial": "N.M.",
                    "last": "Ferguson"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.05.059",
            "firstpage": "3746",
            "issn": "0264410X",
            "lastpage": "3751",
            "pmid": "26051515",
            "pub_year": 2015,
            "title": "Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia",
            "volume": "33"
        },
        "b9000": {
            "authors": [],
            "doi": "10.1016/S0140-6736(15)60721-8",
            "firstpage": "31",
            "issn": "01406736",
            "lastpage": "45",
            "pmid": "25913272",
            "pub_year": 2015,
            "title": "Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial",
            "volume": "386"
        }
    },
    "body_text": [
        {
            "endOffset": 24530,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 24529,
                    "startOffset": 24525
                }
            },
            "secId": "s0020",
            "sentence": "Consequently, post-licensure studies should include pre-immunization serostatus, as requested by WHO\u2019s Global Advisory Committee on Vaccine Safety [13].",
            "startOffset": 24378,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 15874,
            "parents": [],
            "secId": "s0010",
            "sentence": "Cumulative efficacy across both regions was 82% (95% CI, 67\u201390%) for seropositive persons, and 53% (95% CI, 6\u201376%) for seronegative persons.",
            "startOffset": 15734,
            "title": "Data summary"
        },
        {
            "endOffset": 13638,
            "parents": [],
            "secId": "s0005",
            "sentence": "Age groups were defined by age at enrollment and not age at outcome.",
            "startOffset": 13570,
            "title": "Background"
        },
        {
            "endOffset": 23681,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 23680,
                    "startOffset": 23676
                }
            },
            "secId": "s0020",
            "sentence": "Moreover, the incidence rate reductions and number needed to vaccinate were almost identical among seropositive and seronegative persons, indicating vaccine had similar efficiency regardless of serostatus [11].",
            "startOffset": 23471,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 23833,
            "parents": [],
            "secId": "s0020",
            "sentence": "Consequently, it would seem results in both seropositive and seronegative persons could be used to drive public health recommendations for vaccine use.",
            "startOffset": 23682,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 25943,
            "parents": [],
            "secId": "s0025",
            "sentence": "N Halsey did not receive funding for his contribution to the current manuscript; he serves on a data and safety monitoring board for studies of a Norovirus vaccine produced by Takeda, but he has no conflict of interest with regard to dengue vaccines.",
            "startOffset": 25693,
            "title": "Funding source and role of the funding source"
        },
        {
            "endOffset": 22488,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 22487,
                    "startOffset": 22484
                }
            },
            "secId": "s0020",
            "sentence": "Available safety data do not indicate a need to delay vaccine introduction in settings of increased dengue risk, especially because the vaccine will be licensed only among those age 9 years and older where there is little or no suggestion of a safety concern [9].",
            "startOffset": 22225,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 26052,
            "parents": [],
            "secId": "s0025",
            "sentence": "Sanofi Pasteur received a pre-publication version of the current manuscript but otherwise had no other role.",
            "startOffset": 25944,
            "title": "Funding source and role of the funding source"
        },
        {
            "endOffset": 25500,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 25448,
                    "startOffset": 25443
                },
                "b0035": {
                    "endOffset": 25448,
                    "startOffset": 25443
                }
            },
            "secId": "s0020",
            "sentence": "Finally, because heterotypic immunity lasts for approximately two years following natural infection [6,7], follow-up should continue for longer time periods.",
            "startOffset": 25343,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 14770,
            "parents": [],
            "secId": "s0010",
            "sentence": "When adjusted for the 2:1 vaccinated:control design, the increased risk of dengue during year 3 among children enrolled at age 2\u20135 years appeared to occur primarily because of a decrease in the number of cases among control children from year 2 to 3, not an increase in cases among vaccinated children (Fig. 2a).",
            "startOffset": 14458,
            "title": "Data summary"
        },
        {
            "endOffset": 22842,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 22771,
                    "startOffset": 22768
                }
            },
            "secId": "s0020",
            "sentence": "Some authors have recommended determining prevaccination serostatus [4], based on both safety and efficacy concerns for seronegative patients.",
            "startOffset": 22700,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 13170,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 13169,
                    "startOffset": 13166
                }
            },
            "secId": "s0005",
            "sentence": "Some authors have questioned whether these findings resulted in part from immune enhancement, such as antibody dependent enhancement (ADE), where incomplete vaccine induced priming of seronegative patients led to subsequent severe disease after natural infection [4].",
            "startOffset": 12903,
            "title": "Background"
        },
        {
            "endOffset": 13878,
            "parents": [],
            "secId": "s0010",
            "sentence": "The protective effect of dengue vaccine against hospitalization for virologically-confirmed dengue (VCD) decreased from the first two to the last three years of follow-up in all age groups and both regions (Fig. 1 and Table 1).",
            "startOffset": 13651,
            "title": "Data summary"
        },
        {
            "endOffset": 12579,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 12509,
                    "startOffset": 12506
                },
                "b0010": {
                    "endOffset": 12536,
                    "startOffset": 12531
                },
                "b0015": {
                    "endOffset": 12536,
                    "startOffset": 12531
                }
            },
            "secId": "s0005",
            "sentence": "A live, attenuated tetravalent dengue vaccine showed efficacy against virologically confirmed dengue (VCD) in a phase 2b trial [1] and phase III trials [2,3] and has now been licensed in 13 countries.",
            "startOffset": 12379,
            "title": "Background"
        },
        {
            "endOffset": 23470,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 23460,
                    "startOffset": 23457
                }
            },
            "secId": "s0020",
            "sentence": "However, as noted above, trial data found that while dengue VE was lower among seronegative than seropositive individuals age 9 years and above, protection was afforded to both with confidence intervals that overlapped (seropositive VE: 82% [95% CI 67\u201390%]; seronegative VE 53% [95% CI, 6\u201376%]) (Ref. [2], Fig. 2).",
            "startOffset": 23156,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 13349,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here we review the clinical trial data and assess potential explanations for the unexpected findings.",
            "startOffset": 13248,
            "title": "Background"
        },
        {
            "endOffset": 21931,
            "parents": [],
            "secId": "s0015",
            "sentence": "Insufficient data exist to make a definitive determination regarding which hypothesis is correct, or whether an entirely different hypothesis best explains the data.",
            "startOffset": 21766,
            "title": "Explanatory hypotheses"
        },
        {
            "endOffset": 24377,
            "parents": [],
            "secId": "s0020",
            "sentence": "The lack of long-term follow up of all VCD cases \u2013 not just hospitalized cases \u2013 and the small cohort with baseline serostatus determined prevent a more complete understanding of whether and to what extent immune enhancement might have occurred.",
            "startOffset": 24132,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 23155,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 23154,
                    "startOffset": 23150
                }
            },
            "secId": "s0020",
            "sentence": "Other authors, including those with the World Health Organization, have accepted dengue vaccine safety in persons aged \u2265 9 years but question its efficacy stating that \u201cthe individual-level benefit of CYD-TDV for seronegative individuals \u2265 9 years of age cannot be quantified with the data available today\u201d [10].",
            "startOffset": 22843,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 14206,
            "parents": [],
            "secId": "s0010",
            "sentence": "Among the 48 individual year data points reported in Table 1, only one involved a relative risk >1.0 that was significant at the 95% confidence level.",
            "startOffset": 14056,
            "title": "Data summary"
        },
        {
            "endOffset": 15433,
            "parents": [],
            "secId": "s0010",
            "sentence": "The data set was too small to assess correlation between baseline serostatus and risk of dengue-associated hospitalization or severe disease.",
            "startOffset": 15292,
            "title": "Data summary"
        },
        {
            "endOffset": 25692,
            "parents": [],
            "secId": "s0025",
            "sentence": "BD Gessner worked for AMP at the time he wrote this manuscript, which received funding from Sanofi Pasteur, the manufacturer of the dengue vaccine.",
            "startOffset": 25545,
            "title": "Funding source and role of the funding source"
        },
        {
            "endOffset": 13569,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13558,
                    "startOffset": 13553
                },
                "b0015": {
                    "endOffset": 13558,
                    "startOffset": 13553
                }
            },
            "secId": "s0005",
            "sentence": "We have based our analysis on published methods, including relative risk \u2013 rather than vaccine efficacy [VE] \u2013 of hospitalization in vaccinated versus control populations [2,3] (Table 1).",
            "startOffset": 13382,
            "title": "Background"
        },
        {
            "endOffset": 14961,
            "parents": [],
            "secId": "s0010",
            "sentence": "A second possible signal of increased risk among vaccinated children was seen during year 4 among Asian children age 9\u201311 years, with a non-significant relative risk of 2.0 (95% CI, 0.54\u201311).",
            "startOffset": 14770,
            "title": "Data summary"
        },
        {
            "endOffset": 12902,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the Asian setting, an increase in hospitalized cases \u2013 and the subset that were severe \u2013 occurred among the youngest age group during the third year of follow-up.",
            "startOffset": 12737,
            "title": "Background"
        },
        {
            "endOffset": 15227,
            "parents": [],
            "secId": "s0010",
            "sentence": "Unlike children age 2\u20135 years, this increase occurred primarily from an increase in cases among vaccinated children; also, unlike children aged 2\u20135 years, the relative level of cumulative cases remained lower among vaccinated children for each study year (Fig. 2c).",
            "startOffset": 14962,
            "title": "Data summary"
        },
        {
            "endOffset": 23942,
            "parents": [],
            "secId": "s0020",
            "sentence": "Additionally, at an ecological level, no relationship exists between country seropositivity and VE (Fig. 3).",
            "startOffset": 23834,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 24882,
            "parents": [],
            "secId": "s0020",
            "sentence": "Finally, if immune enhancement has occurred, it may not be unique to the currently licensed vaccine.",
            "startOffset": 24782,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 22699,
            "parents": [],
            "secId": "s0020",
            "sentence": "Because published data do not suggest dengue vaccine has safety concerns in persons age 9 years and older, public health programs do not need to document individual level serostatus in advance of vaccination.",
            "startOffset": 22491,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 13247,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 13246,
                    "startOffset": 13243
                }
            },
            "secId": "s0005",
            "sentence": "The lead clinical trial investigators have disputed this interpretation [5].",
            "startOffset": 13171,
            "title": "Background"
        },
        {
            "endOffset": 24131,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 24130,
                    "startOffset": 24126
                }
            },
            "secId": "s0020",
            "sentence": "We think at-risk countries should assess the potential role for dengue vaccine in public health immunization programs as recommended by WHO and the Strategic Advisory Group of Experts [12].",
            "startOffset": 23942,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 25167,
            "parents": [],
            "secId": "s0020",
            "sentence": "Manufacturers for all vaccines under development should collect sufficient information on baseline serostatus to evaluate this issue during more definitive phase 3 trials, and they should include a sufficient number of subjects to stratify by baseline serostatus, age, and study year.",
            "startOffset": 24883,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 25342,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 25287,
                    "startOffset": 25283
                }
            },
            "secId": "s0020",
            "sentence": "Because baseline serostatus may vary by serotype, and vaccine serotypes may elicit different immunologic responses [14], studies also should allow stratification by serotype.",
            "startOffset": 25168,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 26141,
            "parents": [],
            "secId": "s0025",
            "sentence": "All editorial control remained with the authors, who made the final decision to publish.",
            "startOffset": 26053,
            "title": "Funding source and role of the funding source"
        },
        {
            "endOffset": 15291,
            "parents": [],
            "secId": "s0010",
            "sentence": "Baseline serostatus was obtained for a subset of study subjects.",
            "startOffset": 15227,
            "title": "Data summary"
        },
        {
            "endOffset": 22103,
            "parents": [],
            "secId": "s0015",
            "sentence": "There is a need for additional post-licensure studies that document vaccine impact by baseline serostatus, with a sufficiently large number of subjects to stratify by age.",
            "startOffset": 21932,
            "title": "Explanatory hypotheses"
        },
        {
            "endOffset": 14457,
            "parents": [],
            "secId": "s0010",
            "sentence": "Specifically, during analysis of the Asian data, a 7.5-fold increase in risk was identified in vaccinated compared to control children age 2\u20135 years during year 3 of follow-up, a risk that subsequently decreased during years 4\u20135 (Fig. 1 and Table 1).",
            "startOffset": 14207,
            "title": "Data summary"
        },
        {
            "endOffset": 13382,
            "parents": [],
            "secId": "s0005",
            "sentence": "We did not conduct any modeling.",
            "startOffset": 13350,
            "title": "Background"
        },
        {
            "endOffset": 15994,
            "parents": [],
            "secId": "s0010",
            "sentence": "On a population level, no correlation existed between baseline seropositivity prevalence and vaccine efficacy (Fig. 3).",
            "startOffset": 15875,
            "title": "Data summary"
        },
        {
            "endOffset": 15733,
            "parents": [],
            "secId": "s0010",
            "sentence": "However, vaccine provided protection against all VCD among baseline seropositive persons in Asia (VE, 79%; 95% CI 47\u201393%) and Latin America (VE, 81%; 95% CI, 71\u201388%) and also provided protection to seronegative persons in Asia (VE, 62%; 95% CI \u221221 to 88%) and Latin America (VE, 43%; 95% CI 62\u201380%).",
            "startOffset": 15434,
            "title": "Data summary"
        },
        {
            "endOffset": 22222,
            "parents": [],
            "secId": "s0020",
            "sentence": "While awaiting more definitive results, we think the data support two recommendations.",
            "startOffset": 22136,
            "title": "Implications and recommendations"
        },
        {
            "endOffset": 12736,
            "parents": [],
            "secId": "s0005",
            "sentence": "Unlike Latin American countries, where enrollment age was 9\u201316 years, participating trial sites in Asian countries enrolled children from age 2 to 14 years.",
            "startOffset": 12580,
            "title": "Background"
        },
        {
            "endOffset": 14056,
            "parents": [],
            "secId": "s0010",
            "sentence": "Nevertheless, cumulative relative risk for vaccinated versus control children was <1.0 for all groups except children age 2\u20135 years in both Asia (CYD14) and Thailand (CYD23/57).",
            "startOffset": 13879,
            "title": "Data summary"
        },
        {
            "endOffset": 24781,
            "parents": [],
            "secId": "s0020",
            "sentence": "Additionally, it will be important to follow study children for longer than age 5 years to determine long-term efficacy against VCD and to determine if some children based on age or serostatus have an increased risk of hospitalized or severe disease.",
            "startOffset": 24531,
            "title": "Implications and recommendations"
        }
    ],
    "docId": "S0264410X17305881",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "bgessner@aamp.org",
                "first": "Bradford D.",
                "initial": "B.D.",
                "last": "Gessner"
            },
            {
                "email": null,
                "first": "Neal",
                "initial": "N.",
                "last": "Halsey"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.05.003",
        "firstpage": "3452",
        "issn": "0264410X",
        "keywords": [
            "Adverse events following immunization",
            "Clinical trial",
            "Dengue",
            "Immunization",
            "Safety",
            "Vaccine"
        ],
        "lastpage": "3456",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?"
    }
}